IM Cannabis Corp. (NASDAQ: IMCC) (CSE:IMCC) released financial results for its second quarter ended June 30, 2022, revealing revenues increased 114% year-over-year to CA$23.8 million ($18.43 million).
Q2 2022 Financial Results
vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today